Yesterday Advanced Medical Optics Inc. (AMO; Santa Ana, CA) announced its bid for Bausch...
July 6th, 2007
0
FDA has approved a second hip resurfacing implant, the New York Times reports. The Cormet hip resurfacing system, a joint venture of Stryker and the U.K.'s Corin Group, joins Smith & Nephew's Birmingham system on the U.S. market. (Corin developed the Cormet and Stryker holds U.S. distribution rights.) Stryker says it expects to begin marketing it in September. Hip resurfacing is an alternative to total hip replacement. Its main advantage is that it preserves more of the thigh bone. About 10-15% of hip replacement patients could benefit from hip resurfacing, analysts estimate.
July 5th, 2007
0
Covidien, the device company spun off yesterday from Tyco International, saw its shares rise on its first day of trading as its own entity. It could be a harbinger of success for a firm no longer burdened by the wrongdoings and excesses of its corporate parent. But the story isn't that simple, says Boston Globe columnist Steven Syre in a piece today. When what is now Covidien was part of the Tyco conglomerate, Wall Street and the public had no idea how the unit performed in and of itself; only overall results for the corporation were reported. So if there were any problems with performance, they didn't have as much of an effect on Tyco's stock price as they would on Covidien's price going forward. Syre says some on the Street believe that when it was part of Tyco, Covidien invested less in R...
July 3rd, 2007
0
Intravascular Ultrasound (IVUS) technology has been around for about 10 years, but many doctors haven't seen it as necessary. That may be changing now that it has been found to provide better views of stent placements than angiograms, reports the Star Tribune of Minneapolis. With fears that drug-eluting stents may help cause blood clots, properly placing them has become particularly important. IVUS enables cardiologists to see whether the stent has been fully expanded against the artery wall; angiograms can't do that. If it is not fully expanded, blood and debris can get caught between the stent and the artery wall, possibly leading to a blood clot. Also helping is that Boston Scientific and Volcano Corp. (Rancho Cordova, CA) have introduced easier-to-use units in the past year.
July 2nd, 2007
0
After efforts to recover from a huge corporate scandal, Tyco International is splitting up. The move will create three spin offs--Covidien, Tyco Electronics, and Tyco International. Covidien (Mansfield, MA) will become one of the largest medical equipment manufacturers in the world. According to the Newark Star Ledger, its sales of ventilators and respiratory management products increased 4.2% to $704 million during the first half of the year. The Boston Globe is also reporting that Covidien is making a clear effort to distinguish itself from the tarnished Tyco name via billboards and other advertisements. The company markets a range of healthcare products under brand names including Autosuture, Kendall Healthcare, and Syneture.
June 29th, 2007
0
At a Senate hearing on industry gifts to doctors yesterday, some Senate Democrats said they would push for legislation that would create a federal registry of such gifts. The New York Times article about this is almost entirely about the drug industry, but it refers to "legislation that would create a national registry of gifts and payments to doctors by the makers of drugs and medical devices." Yet the uproar doesn't seem to be about medical devices; that was the only mention of them in the whole piece. The device industry's trade associations need to weigh in on this quickly.
June 28th, 2007
0
A device that freezes part of the heart in order to stop abnormal heart rhythms has been recommended for approval by an FDA advisory panel, the Associated Press reports. The Cardiac Cryoablation System from Cryocor Corp. (San Diego) uses a catheter to send nitrous oxide into part of the heart. The nitrous oxide freezes tissues and creates lesions in the upper chamber that ablate areas responsible for the abnormal rhythms. Similar technologies are available that use radiofrequency energy instead of cold. The panel recommended that the company create a patient registry and conduct follow-up studies. The agency usually, but not always, follows the advice of its panels.
June 28th, 2007
0
FDA announced it has cleared for marketing the Binax NOW Malaria Test, the first rapid test for malaria authorized for use in the United States. The test, made by Binax Inc., a subsidiary of Inverness Medical Innovations, Inc. (Scarborough, ME), can produce results in 15 minutes from a few drops of whole blood. It can also differentiate types of malaria. Previously, technicians had to examine blood samples under a microscope. While malaria is not common in this country, it is common in other parts of the world, and Americans who travel abroad may be susceptible to it.
June 27th, 2007
0
Billion-dollar deals used to be pretty rare in the medical device industry. We would see one or two a year, usually for not much more than $1 billion. But the Boston Scientific-Guidant deal changed all that. Now any company of any size can be considered a potential acquisition, and a number of multibillion-dollar acquisitions have been made in the past 12 months. The Guidant deal may also have encouraged device CEOs to overspend, if they think their target is a particularly good fit. That may be the case with Roche Diagnostics, which according to Bloomberg News, has offered $3 billion to buy another diagnostics company, Ventana Medical Systems Inc. (Tuscon, AZ). That works out to $75 a share, which is a whopping 45% higher than Ventana's closing share price yesterday. Why would Roche pay that much of a premium? Because Ventana makes screening tests that...
June 26th, 2007
0

Shelhigh Inc. on Friday settled its dispute with FDA over possible contamination of its tissue-based products, reports the Star-Ledger of Newark, NJ. It signed a consent decree to stop distributing products until it meets GMP requirements. It does not have to recall its products, as FDA requested, and can resume certain phases of manufacturing. But it does have to hire outside consultants to audit its facilities.

June 25th, 2007
0